ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ODX Omega Diagnostics Group Plc

2.20
0.00 (0.00%)
17 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Omega Diagnostics Group Plc LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.20 2.00 2.40 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Omega Diagnostics Share Discussion Threads

Showing 451 to 473 of 37200 messages
Chat Pages: Latest  24  23  22  21  20  19  18  17  16  15  14  13  Older
DateSubjectAuthorDiscuss
24/1/2012
16:11
Something fishy going on - we get a couple of small sized purchases and now there is NO stock available to buy online without a negotiated trade - not a single share.

Maybe the source of sub-placing price stock has dried up. Could see a spike soon.

EDIT: obviously MMs needed a breather as normal service is resumed (16:18) although there are only 15K available online at the full offer.

longshanks
23/1/2012
11:22
Yes. I thought the sell off of ODX was overdone even if growth in sales of IDS-iSYS was slowing. It's doubly overdone IMO on today's positive news about IDS-iSYS.
somerset lad
23/1/2012
10:00
somerset lad - thanks very much a very interesting post. So reading between the lines it's fairly good news for us at ODX then?
monis
23/1/2012
09:30
MONIS, the link between ODX and IDH is that ODX's growth strategy involves (in part) developing product for IDH's IDS-iSYS platform; and the more successful IDH is in selling its IDS-iSYS systems, the larger the addressable market for ODX if its product development succeeds.

ODX holders therefore do not care about: (a) the prospects for IDH's vitamin D tests (which account for around half of IDH's revenues); or (b) IDH's margins in selling IDS-iSYS systems; although both of these points are very important for IDH holders. (ODX holders are interested indirectly in IDH investing to increase the range of tests available on IDS-iSYS systems and in IDH investing in sales and marketing for the IDS-iSYS system, since both of these ought to drive sales of the IDS-iSYS system. In turn, therefore, it helps ODX if IDH is successful generally and generates enough cash to fund product development and marketing.)

Today's IDH statement is bearish on vitamin D testing (but we don't care), bullish on IDS-iSYS (as Stegrego notes above; very good news), and also makes encouraging noises on new product development, marketing investment and cash generation.

This message (vitamin D bad; IDS-iSYS good) contrasts with IDH's warning on 28.11.11 which could be read as bearish on both of these components of the IDH business and led (IMO) to the sustained fall in the ODX share price

somerset lad
23/1/2012
08:37
Is it possible that we at ODX could be taking business away from them? Or are we not linked like that?
monis
23/1/2012
08:28
IDH are positive on IDS -iSYS.

Investment in new product development will increase in the new financial year. The Company believes that the IDS-iSYS proposition remains strong and fulfils a significant unmet market need particularly for the small and medium sized laboratories. Increasing the range of tests available for use on the IDS-iSYS platform will continue to enhance the value of the system.

The first ever automated test for 1,25-Dihydroxy Vitamin D is expected to be launched around the end of the current financial year and IDS-iSYS tests for hypertension (Renin and Aldosterone) are expected to be launched in the first quarter of the next financial year. This will make the IDS-iSYS the first automated system with both these tests.

During the next financial year the Company expects to launch an additional three new tests in the areas of bone, hypertension and diabetes, further expanding the menu and differentiating the platform. The Company will also continue to pursue additional out-licensing opportunities for the IDS-iSYS technology.

Outlook

The Board expects overall revenues to show similar year on year growth in the new financial year with the decline in manual test sales being offset by increased IDS-iSYS revenues arising from new placements and additional products becoming available on the IDS-iSYS system. As a result of the combined impact of the factors and actions outlined above, the Board expects profit growth to resume in the new financial year.

stegrego
23/1/2012
08:24
IDH been absolutely hammered this morning. Expected to see a knock-on effect on ODX from that, but not yet, it's actually up a bit.
codek
21/1/2012
13:01
Something has happened to increase volumn?
leedslad001
20/1/2012
18:56
Im still following here.

Every beaten up small cap has a chart like this one this week, in fact most have had stronger rises, so i wouldn't read too much into it.

davydoo
20/1/2012
16:51
You can tell this is off the radar as only 4 of us here. lol
longshanks as you say,I would like a few more myself on the cheap :-)

leedslad001
20/1/2012
15:47
Nice to see that second tick up.
monis
20/1/2012
15:40
Damn all these other interlopers. I've been steadily acquiring stock and I still don't have as many as I would like.

Still nice to have a bit of support for a change: has there been a tip somewhere?

longshanks
13/1/2012
15:38
£500 top up today
leedslad001
12/1/2012
12:59
I wouldn't exactly say IDH is struggling. Struggling to maintain the stellar rate of growth seen over the last couple of years maybe but that slowdown is more to do with growing competition than tightening markets.

Market for ODX is still fairly nascent and plenty of growth potential exists. If they get to be valued > £100m in a few years time then I for one will be very happy.

longshanks
12/1/2012
09:08
IDH struggling.....specific issues or general trend in sector?
trustman
10/1/2012
14:49
Wish i had some spare cash i would be buying.
Spoke to the company about the share price decline, Small retail sellers at the moment so mm's can mark it down to suit themselves as no buying pressure.

leedslad001
10/1/2012
09:53
In the last results.

As noted in the recent trading update the visibility of Allergozyme(R) export sales remains uncertain and customer evaluations in certain overseas markets are taking longer than first anticipated, but the Directors remain confident in this range of products.

Could be a profit warning coming, need to see a trading update.

tech
10/1/2012
09:48
This is getting pretty miserable. Market cap will soon be below the capital raised last year!

Good time for those buying in but how low will it go?

longshanks
04/1/2012
12:57
Will we get an RNS ?
Wonder who bought them?

leedslad001
04/1/2012
11:27
chunky trade reported: worked sale? That might explain why the price tanked before Xmas.

Could be due a nice rebound soon....one of my 5 for the UK Stock Challenge.

longshanks
22/12/2011
09:21
Happy Christmas to you!
philo124
22/12/2011
09:09
Happy Christmas everyone
leedslad001
06/12/2011
11:16
We know there is a 100000 roll out there as well so the MM's have full control at the moment. Not gonna let them out at a good price.
So anyone with any spare cash is been given a great chance to buy more at the moment.

leedslad001
Chat Pages: Latest  24  23  22  21  20  19  18  17  16  15  14  13  Older

Your Recent History

Delayed Upgrade Clock